CBIO - NASDAQ
Crescent Biopharma, Inc.
$17.95
+5.6%Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotCrescent Biopharma, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Crescent Biopharma, Inc. Income Statement
CBIO • NASDAQ
| Crescent Biopharma, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||
10.8M | 0.0 | 10K | 75K | 1.2M | 10.2M | 0.0 | 0.0 | 0.0 | 18.5K | 20.1M | 15M | 4M | 15.3M | 3.8M | |
GROSS PROFIT | |||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (951.6K) | (899.3K) | (275.1K) | (263.5K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
10.8M | 0.0 | 10K | 75K | 1.2M | 10.2M | -899.3K | -275.1K | -263.5K | 0.0 | 20.1M | 15M | 4M | 15.3M | 0.0 | |
OPERATING INCOME | |||||||||||||||
(163.5M) | (49.9M) | (39.3M) | (47.5M) | (64.6M) | (61.7M) | (61.4M) | (51.5M) | (33.9M) | (31.9M) | (32.9M) | (26.2M) | (14.6M) | (11.6M) | (9.9M) | |
(25.4M) | (16.3M) | (19.2M) | (19.1M) | (17.1M) | (16.7M) | (14.4M) | (11.4M) | (9.8M) | (8.7M) | (7.8M) | (6.6M) | (2.9M) | (2.2M) | (2.1M) | |
(138.1M) | (28.1M) | (20.1M) | (28.4M) | (47.5M) | (44.9M) | (47M) | (40.1M) | (24.1M) | (23.3M) | (25.1M) | (19.6M) | (11.7M) | (9.4M) | (7.8M) | |
-152.6M | -49.9M | -39.3M | -47.4M | -63.4M | -51.5M | -61.4M | -51.5M | -33.9M | -31.9M | -12.8M | -11.1M | -10.6M | 3.6M | -6.1M | |
PRE-TAX INCOME | |||||||||||||||
(2.2M) | (852K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
690K | 149.2K | 2.4M | 714.5K | 19.8K | 482.5K | 0.0 | 0.0 | 0.0 | 103.6K | 0.0 | 0.0 | 894.0 | 21K | 8.4K | |
(0.0) | (5.5M) | (637.0) | (443.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -262.0 | -1K | -78.0 | (0.0) | |
690K | 1.4M | 2.4M | 715K | 19.8K | 482.5K | 3.5M | 3.2M | 651.2K | 103.6K | 15.3K | 18K | -132.0 | 20.9K | -28.4K | |
-151.9M | -48.5M | -36.9M | -46.7M | -63.4M | -51M | -57.9M | -48.3M | -33.3M | -31.8M | -12.8M | -11.1M | -10.6M | 3.7M | -6.1M | |
NET INCOME | |||||||||||||||
(2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3.8M | (3.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-153.9M | -48.5M | -36.9M | -46.7M | -63.4M | -51M | -54.1M | -48.3M | -33.3M | -31.8M | -12.8M | -11.1M | -10.6M | 3.7M | -6.1M |
SEC Filings
CBIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 29, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
S-1 S-1 N/A | January 07, 2026 | January 07, 2026 | ||
8-K 8-K 2025 N/A | December 04, 2025 | December 02, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your CBIO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.